OOIR: Observatory of International Research

Papers

(The median citation count of Cancer and Metastasis Reviews is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners	100
Glioma: molecular signature and crossroads with tumor microenvironment	90
Checkpoint inhibitor therapy for metastatic triple-negative breast cancer	71
Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer	70
Secreted frizzled-related protein 2: a key player in noncanonical Wnt signaling and tumor angiogenesis	61
The adipocyte microenvironment and cancer	60
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers	54
Targeting KRAS in pancreatic cancer: new drugs on the horizon	52
The obesity-breast cancer link: a multidisciplinary perspective	51
Neuroblastoma and the epigenome	51
Lipid metabolism reprogramming in renal cell carcinoma	49
The comprehensive landscape of miR-34a in cancer research	45
Gastrointestinal stromal tumor: a review of current and emerging therapies	43
The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance	41
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions	40
The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions	39
An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression	37
Targeting the cytoskeleton against metastatic dissemination	36
Neutrophil-derived granule cargoes: paving the way for tumor growth and progression	36
Inflammatory bowel disease and carcinogenesis	35
Rethinking the biology of metastatic melanoma: a holistic approach	33
Role of non-coding RNAs in tumor progression and metastasis in pancreatic cancer	32
Chemokines orchestrate tumor cells and the microenvironment to achieve metastatic heterogeneity	31
The role of microbiome in pancreatic cancer	30
The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options	30

Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma—backbone or add-on in immune-oncology?	28
Nanoparticle-mediated cancer cell therapy: basic science to clinical applications	27
Obesity: a perfect storm for carcinogenesis	27
Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis	27
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution	25
Platelets as messengers of early-stage cancer	25
Metformin: review of epidemiology and mechanisms of action in pancreatic cancer	24
Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux	24
A bi-directional dialog between vascular cells and monocytes/macrophages regulates tumor progression	23
Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance	23
The role of the metabolite cargo of extracellular vesicles in tumor progression	23
Role of myeloid-derived suppressor cells in metastasis	23
Exosomes: a new perspective in EGFR-mutated lung cancer	23
Adipocytokines and disease progression in endometrial cancer: a systematic review	22
The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers	21
Dormant cancer cells: programmed quiescence, senescence, or both?	21
Visualizing cancer extravasation: from mechanistic studies to drug development	21
Mucins reprogram stemness, metabolism and promote chemoresistance during cancer progression	21
Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance	20
Safety of radiosurgery concurrent with systemic therapy (chemotherapy, targeted therapy, and/or immunotherapy) in brain metastases: a systematic review	20
Targeting DNA damage repair pathways in pancreas cancer	19
Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations	19
The involvement of oncobiosis and bacterial metabolite signaling in metastasis formation in breast cancer	19
The role of tumor heterogeneity in immune-tumor interactions	19
Epigenetic modulation of immunotherapy and implications in head and neck cancer	19
Resolution medicine in cancer, infection, pain and inflammation: are we on track to address the next Pandemic?	19
Extracellular citrate and metabolic adaptations of cancer cells	19
Informing the new developments and future of cancer immunotherapy	19
Mechanistic insights into the interplays between neutrophils and other immune cells in cancer development and progression	19
Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors	18
Pancreatic cancer: branched-chain amino acids as putative key metabolic regulators?	18
The role of metabolic ecosystem in cancer progression — metabolic plasticity and mTOR hyperactivity in tumor tissues	18
Breast cancer microenvironment and obesity: challenges for therapy	18
Debris-stimulated tumor growth: a Pandora’s box?	17
Natural compounds targeting nuclear receptors for effective cancer therapy	17
What do cellular responses to acidity tell us about cancer?	16
Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology	16
Regulation of dormancy during tumor dissemination: the role of the ECM	16
Short-chain fatty acids in cancer pathogenesis	16
Macrophages in multiple myeloma: key roles and therapeutic strategies	15
Insights into the role of senescence in tumor dormancy: mechanisms and applications	15
MicroRNAs as a clue to overcome breast cancer treatment resistance	15
A multidisciplinary perspective on the complex interactions between sleep, circadian, and metabolic disruption in cancer patients	15
Oral delivery of RNAi for cancer therapy	14
The role of obesity and bariatric surgery-induced weight loss in breast cancer	14
Glycosylation as a regulator of site-specific metastasis	14
Mesenchymal stromal cell senescence in haematological malignancies	14
MHC heterogeneity and response of metastases to immunotherapy	14
Hypoxia signaling in hepatocellular carcinoma: Challenges and therapeutic opportunities	14
Potential mechanisms of tumor progression associated with postoperative infectious complications	14

The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer	14
Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment	13
Oncobiology and treatment of breast cancer in young women	13
Obesity, cancer risk, and time-restricted eating	13
Emerging roles of epithelial-mesenchymal plasticity in invasion-metastasis cascade and therapy resistance	13
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications	13
The timing of adiposity and changes in the life course on the risk of cancer	12
Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response	12
Physicochemical aspects of the tumour microenvironment as drivers of vasculogenic mimicry	12
The effect of obesity on adipose-derived stromal cells and adipose tissue and their impact on cancer	12
Resveratrol as sensitizer in colorectal cancer plasticity	12
Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets	12
Emerging roles for myeloid immune cells in bone metastasis	11
Decoding human cancer with whole genome sequencing: a review of PCAWG Project studies published in February 2020	11
Connecting the Human Microbiome and Pancreatic Cancer	11
The emerging roles of circular RNAs in vessel co-option and vasculogenic mimicry: clinical insights for anti-angiogenic therapy in cancers	10
Mechanisms behind context-dependent role of glucocorticoids in breast cancer progression	10
Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance	10
Role of myeloid-derived suppressor cells in tumor recurrence	10
Models of pancreatic ductal adenocarcinoma	10
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions	10
Implications of prognosis-associated genes in pancreatic tumor metastasis: lessons from global studies in bioinformatics	10
Nanotechnology-aided advancement in the combating of cancer metastasis	10
Anti-cancer strategies targeting the autotaxin-lysophosphatidic acid receptor axis: is there a path forward?	10
Involvement of redox signalling in tumour cell dormancy and metastasis	9
How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy	9
Autophagy, molecular chaperones, and unfolded protein response as promoters of tumor recurrence	9
Regulation and targeting of SREBP-1 in hepatocellular carcinoma	9
Obesity and cancer—extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases	9
Circadian disruption: from mouse models to molecular mechanisms and cancer therapeutic targets	9
The cure from within? a review of the microbiome and diet in melanoma	9
Oncogenic signaling-mediated regulation of chromatin during tumorigenesis	9
Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective	9
Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation	8
The role of inner nuclear membrane proteins in tumourigenesis and as potential targets for cancer therapy	8
p73 isoforms meet evolution of metastasis	8
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?	8
Model systems in SDHx-related pheochromocytoma/paraganglioma	8
Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation	8
Understanding metabolic alterations and heterogeneity in cancer progression through validated immunodetection of key molecular components: a case of carbonic anhydrase IX	8
Targeting lipid metabolism in cancer: neuroblastoma	8
Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review	8
Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration	8
Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma	8
The role of cancer cell bioenergetics in dormancy and drug resistance	8
The tumor-nerve circuit in breast cancer	8
Notch signaling in malignant gliomas: supporting tumor growth and the vascular environment	8
Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?	8
Impact of posttranslational modifications in pancreatic carcinogenesis and treatments	8
(mis)-Targeting of SWI/SNF complex(es) in cancer	7
Cohesive cancer invasion of the biophysical barrier of smooth muscle	7
Message in the bottle: regulation of the tumor microenvironment via exosome-driven proteolysis	7
Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics	7
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?	7
The paradoxical role of inositol in cancer: a consequence of the metabolic state of a tumor	7
Pancreatic cancer pathology viewed in the light of evolution	7
Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance	7
The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies	7
Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets	7
Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment	6
Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance	6
Epigenetic control of pancreatic cancer metastasis	6
Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy	6
Increasing cancer permeability by photodynamic priming: from microenvironment to mechanotransduction signaling	6
Obesity and cancer	6
Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma	6
Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective	6
Tumor dormancy and disease recurrence	6